ROSIE ANDREW YANG TWITTER TRIAL
The GAP trial has shown that pre-operative chemotherapy is a safe strategy for patients with pancreatic cancer. The DOCTOR trial was the first trial to use PET scans to “tailor” or “personalize” therapy for patients with oesophageal cancer. These studies are aimed at developing personalized, precision therapy for cancer. Both of these national trials include biological substudies with tumour tissue and blood banking and subsequent molecular analyses aimed at answering specific questions, including the identification of biomarkers of response to therapy. He was the Principal Investigator for investigator initiated, multicentre phase II trials in oesophageal (DOCTOR trial) and pancreatic cancer (GAP Trial), funded by the NH&MRC and sponsored by the Australasian Gastrointestinal Trials Group (AGITG). His academic interests have encompassed the areas of 1) clinical research, including randomised controlled clinical trials, 2) laboratory based research, including molecular biology pertinent to upper gastrointestinal disease, pancreatic cancer and melanoma, 3) translational research integrating the laboratory and clinical domains, and 4) health-related quality of life and patient reported outcomes research.Īs a clinical researcher, Prof Barbour has been active in the conduct of clinical trials at Phase I, II and III levels. Professor Barbour’s research interests are in the treatment of cancer. He has expertise in minimally invasive treatments these conditions, including robotic surgery, minimally invasive oesophagectomy, laparoscopic anti-reflux surgery (fundoplication), laparoscopic gastrectomy, and laparoscopic pancreatectomy. Professor Andrew Barbour specializes in the treatment of oesophageal, gastric, and pancreatic diseases, as well as melanoma and soft tissue tumours.
On completion of his training, Dr Barbour worked at the Bristol Royal Infirmary as an Upper Gastrointestinal and Hepatobiliary Surgery Fellow and then as a Surgical Oncology Fellow at the Memorial Sloan-Kettering Cancer Centre, New York. Professor Andrew Barbour is an academic general surgeon who specialises in upper gastrointestinal, pancreatic, melanoma and sarcoma surgery.
0 kommentar(er)
